Amedeo Smart

Free Medical Literature Service


 

Amedeo

Hepatitis C

  Free Subscription

Articles published in
J Infect Dis
    August 2022
  1. GARDNER AR, Ma Y, Bacchetti P, Price JC, et al
    Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment.
    J Infect Dis. 2022 Aug 11. pii: 6650396. doi: 10.1093.
    >> Share

    February 2022
  2. CATLETT B, Hajarizadeh B, Cunningham E, Wolfson-Stofko B, et al
    Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of HCV RNA: a systematic review.
    J Infect Dis. 2022 Feb 12. pii: 6527696. doi: 10.1093.
    >> Share

    September 2021
  3. WARD KM, Falade-Nwulia O, Moon J, Sutcliffe CG, et al
    Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs.
    J Infect Dis. 2021 Sep 20. pii: 6372878. doi: 10.1093.
    >> Share

    June 2021
  4. NDOW G, Cessay A, Cohen D, Shimakawa Y, et al
    Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa.
    J Infect Dis. 2021 Jun 23. pii: 6308183. doi: 10.1093.
    >> Share

    March 2021
  5. ARANDAY-CORTES E, McClure CP, Davis C, Irving WL, et al
    Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa.
    J Infect Dis. 2021 Mar 1. pii: 6154708. doi: 10.1093.
    >> Share

    February 2021
  6. CHUAYPEN N, Jinato T, Avihingsanon A, Chirapongsathorn S, et al
    Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection.
    J Infect Dis. 2021 Feb 17. pii: 6141513. doi: 10.1093.
    >> Share

    January 2021
  7. KHERA T, Du Y, Todt D, Deterding K, et al
    Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C.
    J Infect Dis. 2021 Jan 31. pii: 6124746. doi: 10.1093.
    >> Share

    November 2020
  8. JEYARAJAN AJ, Chung RT
    Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?
    J Infect Dis. 2020;222.
    >> Share

  9. BAJIS S, Applegate TL, Grebely J, Matthews GV, et al
    Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic.
    J Infect Dis. 2020;222.
    >> Share

  10. CHAPPELL CA, Jonas MM
    Hepatitis C Virus in Pregnancy: Are We Ready for Test and Treat?
    J Infect Dis. 2020;222.
    >> Share

  11. THOMAS DL
    30 Years on the Road to Hepatitis C Elimination.
    J Infect Dis. 2020;222.
    >> Share

  12. NAGGIE S, Wyles D
    Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination.
    J Infect Dis. 2020;222.
    >> Share

  13. FALADE-NWULIA O, Sulkowski MS
    Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.
    J Infect Dis. 2020;222.
    >> Share

  14. TROOSKIN SB, Dore G, Kostman J
    We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States.
    J Infect Dis. 2020;222.
    >> Share

  15. ROCKSTROH JK, Boesecke C
    Hepatitis C Virus Treatment as Prevention: Challenges and Opportunities in Men Who Have Sex With Men.
    J Infect Dis. 2020;222.
    >> Share

  16. KAPPUS MR, Wolfe CR, Muir AJ
    Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?
    J Infect Dis. 2020;222.
    >> Share

  17. HALEY DF, Edmonds A, Ramirez C, French AL, et al
    Direct-acting antiviral Hepatitis C treatment cascade and barriers to treatment initiation among US men and women with and without HIV.
    J Infect Dis. 2020 Nov 3. pii: 5952700. doi: 10.1093.
    >> Share

    October 2020
  18. VERGARA C, Valencia A, Thio CL, Goedert JJ, et al
    A multi-ancestry sex stratified genome-wide association study of spontaneous clearance of hepatitis C virus.
    J Infect Dis. 2020 Oct 29. pii: 5943036. doi: 10.1093.
    >> Share

  19. MESALAM AA
    Hepatitis C virus vaccine development: A step forward.
    J Infect Dis. 2020 Oct 11. pii: 5920711. doi: 10.1093.
    >> Share

    September 2020
  20. JORDAN AE, Cleland CM, Wyka K, Schackman BR, et al
    Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.
    J Infect Dis. 2020;222.
    >> Share

  21. LEE AB, Karumberia S, Gilmore A, Williams E, et al
    Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness.
    J Infect Dis. 2020;222.
    >> Share

  22. SHERBUK JE, Knick TK, Canan C, Ross P, et al
    Development of an Interdisciplinary Telehealth Model of Provider Training and Comprehensive Care for Hepatitis C and Opioid Use Disorder in a High-Burden Region.
    J Infect Dis. 2020;222.
    >> Share

  23. JORDAN AE, Cleland CM, Schackman BR, Wyka K, et al
    Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.
    J Infect Dis. 2020;222.
    >> Share

  24. ASSOUMOU SA, Paniagua SM, Linas BP, Wang J, et al
    Rapid Versus Laboratory-Based Testing for HIV and Hepatitis C at a Drug Detoxification Treatment Center: A Randomized Trial.
    J Infect Dis. 2020;222.
    >> Share

  25. WESNER CA, Zhang W, Melstad S, Ruen E, et al
    Assessing County-Level Vulnerability for Opioid Overdose and Rapid Spread of Human Immunodeficiency Virus and Hepatitis C Infection in South Dakota.
    J Infect Dis. 2020;222.
    >> Share

  26. WINETSKY D, Burack D, Antoniou P, Garcia B, et al
    Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.
    J Infect Dis. 2020;222.
    >> Share

  27. SPRINGER SA, Barocas JA, Wurcel A, Nijhawan A, et al
    Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda.
    J Infect Dis. 2020;222.
    >> Share

  28. ROWAN SE, Kamis KF, Beum R, Bryan K, et al
    Viral Hepatitis and Human Immunodeficiency Virus Testing and Linkage to Care for Individuals Enrolled in an Opioid Treatment Program.
    J Infect Dis. 2020;222.
    >> Share

    August 2020
  29. CAPPY P, Lucas Q, Kankarafou N, Sureau C, et al
    No Evidence of HCV-Assisted HDV Propagation in a Large Cohort of Hepatitis C Positive Blood Donors.
    J Infect Dis. 2020 Aug 17. pii: 5893459. doi: 10.1093.
    >> Share

  30. WIJAYA RS, Read SA, Selvamani SP, Schibeci S, et al
    Hepatitis C virus eradication with interferon free, DAA-based therapy results in KLRG1+, hepatitis C virus-specific memory natural killer cells.
    J Infect Dis. 2020 Aug 10. pii: 5890638. doi: 10.1093.
    >> Share

    July 2020
  31. CATLETT B, Bajis S, Starr M, Dore GJ, et al
    Evaluation of the Aptima HCV Quant Dx Assay for HCV RNA detection from finger-stick capillary dried blood spot and venepuncture-collected samples.
    J Infect Dis. 2020 Jul 25. pii: 5876378. doi: 10.1093.
    >> Share

  32. VETTER BN, Reipold EI, Ongarello S, Audu R, et al
    Sensitivity and specificity of rapid diagnostic tests for hepatitis C virus with or without HIV coinfection: a multicentre laboratory evaluation study.
    J Infect Dis. 2020 Jul 2. pii: 5866494. doi: 10.1093.
    >> Share

    June 2020
  33. OGAWA E, Nomura H, Nakamuta M, Furusyo N, et al
    Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals.
    J Infect Dis. 2020 Jun 25. pii: 5862583. doi: 10.1093.
    >> Share

  34. KITABAYASHI J, Shirasaki T, Shimakami T, Nishiyama T, et al
    Upregulation of the Long Non-Coding RNA HULC by Hepatitis C Virus and its Regulation of Viral Replication.
    J Infect Dis. 2020 Jun 9. pii: 5854965. doi: 10.1093.
    >> Share

  35. NAGGIE S, Lusk S, Thompson JW, Mock M, et al
    Metabolomic signature as a predictor of liver disease events in patients with HIV/HCV co-infection.
    J Infect Dis. 2020 Jun 5. pii: 5851922. doi: 10.1093.
    >> Share

    May 2020
  36. ANTHONY DD, Sulkowski MS, Smeaton LM, Damjanovska S, et al
    HCV DAA Therapy in Persons with HIV-HCV Genotype 1 Coinfection Results in High Rate of Sustained Virologic Response and Heterogeneity in Normalization of Soluble Markers of Immune Activation.
    J Infect Dis. 2020 May 15. pii: 5836999. doi: 10.1093.
    >> Share

  37. DASGUPTA S, Imamura M, Gorstein E, Nakahara T, et al
    Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir/pibrentasvir may identify patients for ultra-short treatment duration.
    J Infect Dis. 2020 May 4. pii: 5828592. doi: 10.1093.
    >> Share

    March 2020
  38. BALAGOPAL A, Smeaton LM, Quinn J, Venuto CS, et al
    Intrahepatic Viral Kinetics during Direct-Acting Antivirals for Hepatitis C in HIV Co-infection:The ACTG A5335S Substudy.
    J Infect Dis. 2020 Mar 23. pii: 5810960. doi: 10.1093.
    >> Share

  39. SUN B, Abadjian L, Monto A, Freasier H, et al
    HCV cure in HIV coinfection dampens inflammation and improves cognition through multiple mechanisms.
    J Infect Dis. 2020 Mar 11. pii: 5802775. doi: 10.1093.
    >> Share

  40. AKIYAMA MJ, Lipsey D, Ganova-Raeva L, Punkova L, et al
    A Phylogenetic Analysis of HCV Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy.
    J Infect Dis. 2020 Mar 9. pii: 5801905. doi: 10.1093.
    >> Share

    February 2020
  41. OLBRICH A, Wardemann H, Bohm S, Rother K, et al
    Erratum to: Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C.
    J Infect Dis. 2020 Feb 15. pii: 5736576. doi: 10.1093.
    >> Share

    January 2020
  42. LINAS BP
    Time for a New Approach to Guidance for HIV and HCV Testing Among Persons Who Inject Drugs.
    J Infect Dis. 2020 Jan 30. pii: 5718241. doi: 10.1093.
    >> Share

  43. BULL-OTTERSON L, Huang YA, Zhu W, King H, et al
    HIV and Hepatitis C Virus Infection Testing Among Commercially Insured Persons Who Inject Drugs, United States, 2010-2017.
    J Infect Dis. 2020 Jan 30. pii: 5718242. doi: 10.1093.
    >> Share

  44. GREBELY J, Catlett B, Jayasinghe I, Valerio H, et al
    Time to detection of hepatitis C virus infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a more rapid time to diagnosis.
    J Infect Dis. 2020 Jan 29. pii: 5717213. doi: 10.1093.
    >> Share

  45. CLIPMAN SJ, Duggal P, Srikrishnan AK, Saravanan S, et al
    Prevalence and phylogenetic characterization of hepatitis C among men who have sex with men in India: limited evidence for sexual transmission.
    J Infect Dis. 2020 Jan 9. pii: 5699640. doi: 10.1093.
    >> Share

    November 2019
  46. KOVACS AAZ, Kono N, Wang CH, Wang D, et al
    Association of HLA Genotype With T-Cell Activation in Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus-Coinfected Women.
    J Infect Dis. 2019 Nov 10. pii: 5618844. doi: 10.1093.
    >> Share

    September 2019
  47. ZOU B, Yeo YH, Le MH, Henry L, et al
    Prevalence of viremic HCV infection by age, race/ethnicity, birthplace and disease awareness among viremic persons in the U.S., 1999-2016.
    J Infect Dis. 2019 Sep 27. pii: 5575100. doi: 10.1093.
    >> Share

    August 2019
  48. KOSLOSKI MP, Oberoi R, Wang S, Viani RM, et al
    Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered with Human Immunodeficiency Virus Antiretrovirals.
    J Infect Dis. 2019 Aug 29. pii: 5556482. doi: 10.1093.
    >> Share

    March 2019
  49. KUSEJKO K, Bachmann N, Chaudron SE, Nguyen H, et al
    A systematic phylogenetic approach to study the interaction of HIV-1 with coinfections, non-communicable and opportunistic diseases.
    J Infect Dis. 2019 Mar 4. pii: 5369724. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016